Macro Currents That Shaped the First Half of the Decade

Happy New Year! Let's hope the second half of the decade is a less bumpy ride than the first half. If you work in tools and diagnostics, you've probably spent the last few years bouncing between two emotions: 1) We're building the future. 2) Why does the future keep moving the goalposts?

Both can be true. Over the last few years, we have operated in a space defined by major cross-currents, compared to a much more predictable previous decade.

These macro forces quite violently shaped the space, from what gets funded to what becomes "standard of care."

If you've listened to business podcasts over the last five years — whether they're about tech, markets, or healthcare — you've heard two themes on repeat: AI, COVID, and inflation / affordability. I had ChatGPT conduct an interesting analysis of the top 50 business podcasts and rate the mindshare of various currents in the first half of the decade. Here is what it came up with:

Table 1: A force-ranked list of "most discussed business-podcast megatrends" (first half of the 2020s)

Scoring based on ubiquity across stakeholders, persistence, crossover with other topics, and structural impact: changes in how business operates, rather than headlines alone.

Based on this ranking, we'll touch on the top three as part of the general currents that affected biotech.

Part 1: The First Half of the Decade

The last five years were a masterclass in how much biotech outcomes are driven by macro conditions.

• 2020–2021: risk-on, high beta, abundant financing in light of the pandemic (Current #2), and a market that rewarded promise more than proof.
• 2022–2024: tightening, multiple compression, and fewer exits = survival mode (Current #3). This wasn't just "a down market." It was a reset of what investors demanded.
• 2025+: mixed signals — selective reopening, but not a return to the party. The bar didn't drop; it moved. AI is driving many discussions about where value hides in the future (i.e., interpretation, Current #1).

The strategic implication: if biotech is a capital cycle, then Tools & Dx must be built to perform across the cycle, not just at the peak.

Part 2: The Macro Currents That Defined the Era

These three currents reshaped the biotech ocean floor.

Current #1 — AI Went From Feature to Force of Nature

The key shift wasn't simply that "AI got better." It's that AI became a new layer of labor and decision-making, not just software. AI is rapidly turning into:

• a productivity multiplier for knowledge work
• a decision-support layer across workflows
• a competitive weapon in markets where iteration speed matters

The practical takeaway isn't "have an AI initiative." That's already outdated. The shift is toward AI-native workflows: organizations, products, and services are now designed from the ground up to assume AI is always present and always learning. If that sounds abstract, here's the concrete version: AI doesn't just change what products do. It changes how products get built, sold, validated, and trusted.

Current #2 — The Pandemic Didn't End. It Rewired the World.

COVID created lasting infrastructure and lasting scar tissue. It changed expectations around:

• supply chains and resilience; strategic stockpiles are back
• institutional trust and distrust
• emergency policy tools, now normalized
• remote-first infrastructure, for better and worse

Most importantly for our space, the pandemic made diagnostics visible to the public in a way the category rarely achieves. Testing became dinner-table conversation. That visibility was messy, politicized, and sometimes painful, but it was still visibility. And that's why I think something interesting happened in 2025: diagnostics started to steal share of mind again. Not because of better technology alone, but because the ecosystem began to refocus on evidence, access, workflow, reimbursement, and distribution.

The strategic ripple: tools companies that serve clinical customers feel that pull next. Illumina's revenue growth was driven almost solely by diagnostics customers, but not enough to offset pressure from research and applied customers. When clinical testing is taken seriously, the toolchain that enables it gets re-rated too, and hopefully this will result in a rebound for the tools space in the second half of the decade.

Current #3 — Free Money Died, and With It, "Growth at All Costs"

This was the macro gut punch that reshaped biotech behavior. When inflation rose and the cost of capital reset, the value of long-dated promises dropped. Capital became selective. Duration risk got punished. And the new message became brutally consistent: show me revenue, margins, and outcomes — now.

Two durable trends flow from that:

1. Capital discipline becomes an operating condition, not a phase.
2. Outcomes evidence becomes the price of admission.

That second point is the one many teams still underestimate. It's no longer enough to be analytically impressive. In healthcare, especially diagnostics, your product needs to win a three-front war:

• clinical utility
• economic utility
• operational utility

Not in theory. In the real world, with messy data, staffing constraints, budget silos, and risk committees.

Other Currents Worth Naming, Without Turning This Into a Textbook

There are more tides beneath the surface:

• regulatory whiplash; rules can move faster than product cycles
• industrial policy; government shaping markets, not just refereeing them
• social trust dynamics; science communication and misinformation
• energy + compute constraints; AI's physical footprint is real

But we don't need to list everything. We need to ask the strategic question: What do these currents do to Tools & Dx specifically?

The winners won't just sell technology. They'll sell operational certainty. Tools players sit in a paradoxical position: they're often described as "picks and shovels," yet they're increasingly held to clinical-grade expectations: validation, traceability, evidence, and workflow integration. Instead of considering that a threat, they should consider it a roadmap to lean into.

How to Win in the Late 2020s

If the first half of the decade taught us anything, it's that Tools & Dx leaders should build for an ocean where:

• capital is disciplined
• evidence is expensive
• AI is increasingly everywhere and governed
• regulation is volatile
• workflows, not specs, decide adoption

So what do you do?

1. Sell outcomes, not features.
2. Start with the end in mind, especially regulatory and reimbursement.
3. Make evidence generation part of the product.
4. Design for fragmented markets and hybrid care models.
5. Treat AI as infrastructure: integrate, validate, monitor.

In the end, the winners will be the companies built to thrive when the currents keep moving.